Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
(R,S)-ketamine elicits rapid-acting and sustained antidepressant actions in treatment-resistant patients with depression. (R)-ketamine produces longer-lasting antidepressant effects than (S)-ketamine in rodents; however, the precise molecular mechanisms underlying antidepressant actions of (R)-ketamine remain unknown. Using isobaric Tag for Relative and Absolute Quantification, we identified nuclear receptor-binding protein 1 (NRBP1) that could contribute to different antidepressant-like effects of the two enantiomers in chronic social defeat stress (CSDS) model. NRBP1 was localized in the microglia and neuron, not astrocyte, of mouse medial prefrontal cortex (mPFC). (R)-ketamine increased the expression of NRBP1, brain-derived neurotrophic factor (BDNF), and phosphorylated cAMP response element binding protein (p-CREB)/CREB ratio in primary microglia cultures thorough the extracellular signal-regulated kinase (ERK) activation. Furthermore, (R)-ketamine could activate BDNF transcription through activation of CREB as well as MeCP2 (methyl-CpG binding protein 2) suppression in microglia. Single intracerebroventricular (i.c.v.) injection of CREB-DNA/RNA heteroduplex oligonucleotides (CREB-HDO) or BDNF exon IV-HDO blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. Moreover, microglial depletion by colony-stimulating factor 1 receptor (CSF1R) inhibitor PLX3397 blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. In addition, inhibition of microglia by single i.c.v. injection of mannosylated clodronate liposomes (MCLs) significantly blocked the antidepressant-like effects of (R)-ketamine in CSDS susceptible mice. Finally, single i.c.v. injection of CREB-HDO, BDNF exon IV-HDO or MCLs blocked the beneficial effects of (R)-ketamine on the reduced dendritic spine density in the mPFC of CSDS susceptible mice. These data suggest a novel ERK-NRBP1-CREB-BDNF pathways in microglia underlying antidepressant-like effects of (R)-ketamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Effects of (R)-ketamine and (S)-ketamine on the BDNF activation. A, B The luciferase assay for BDNF exon IV promoter. A BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (0.1, 1.0, and 10 μM) or (S)-ketamine (0.1, 1.0, and 10 μM). The data are the mean ± SEM (n = 6). **P < 0.01; ***P < 0.001 compared to vehicle group. $P < 0.05; $$P < 0.01; $$$P < 0.001 (one-way ANOVA). B BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) [or (S)-ketamine (10 μM)] with or without mutation (Mut) plasmids. The data are the mean ± SEM (n = 9 or 10). **P < 0.01; ***P < 0.001 (one-way ANOVA). C BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) with or without siRNA-CREB plasmids. The data are the mean ± SEM (n = 4). **P < 0.01; ***P < 0.001 (one-way ANOVA). D BDNF exon IV promoter activity in the HEK293T cells treated with (R)-ketamine (10 μM) with or without CREB-HDO or BDNF exon IV-HDO. The data are the mean ± SEM (n = 10). **P < 0.01; ***P < 0.001 (one-way ANOVA). E ChIP-PCR assay for BDNF IV promoter. The p-CREB protein–DNA crosslinking samples were obtained from the primary microglia treated with vehicle, (R)-ketamine (10 μM), or (S)-ketamine (10 μM) via co-immunoprecipitating with anti-p-CREB. PCR was carried out by using BDNF exon IV promoter primer. The data are the mean ± SEM (n = 4). *P < 0.05; ***P < 0.001 (one-way ANOVA). F The immunofluorescence for p-CREB and MeCP2 in the LPS (1 µg/mL)-treated primary microglia with (R)-ketamine (10 µM) or (S)-ketamine (10 µM). Scale bar = 50 μm. G Expression of NRBP1, BDNF, MeCP2, and the ratio of p-CREB/CREB in the LPS-treated primary microglia with (R)-ketamine (10 µM) or (S)-ketamine (10 µM). The data are the mean ± SEM (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001 (one-way ANOVA).](https://figures.cochat.ai/paper-figures/34f3f7ee63654bae9addbb01b553d300/microglial-erk-nrbp1-creb-bdnf-signaling-in-sustained-antidepressant-actions-of-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies using pharmacological inhibitors or genetic ablation models of microglia have demonstrated that the absence or inhibition of these cells completely abolishes the antidepressant effects of ketamine, emphasizing their essential role in the drug’s mechanism of action [81].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This phosphorylation is a key step in upregulating BDNF transcription, a pivotal factor in mediating synaptic plasticity and promoting resilience against stress-related depressive behaviors [81].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, (R)-ketamine’s effect on microglia has been shown to involve suppression of pro-inflammatory mediators, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which contribute to neuroinflammation [81,83].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“microglia (3) also play a role, with ketamine increasing the expression of Nuclear Receptor Binding Protein 1 (NRBP1) and phosphorylated cAMP response element-binding protein (CREB), leading to an increased transcription of BDNF.”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This anti-inflammatory property of (R)-ketamine may enhance the functional role of microglia in supporting neuronal health, reducing oxidative stress, and promoting synaptic connectivity [81,83].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [81]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“[5] reported rapid-acting and sustained antidepressant effects of (R,S)-ketamine in patients with depression.”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
Tang, Y., & Le, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9070-5 · Cited by 2,190 · cited 1×
“Microglia can produce either cytotoxic or neuroprotective effects [67].”
BackgroundElmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968 · cited 1×
“Effect of microglia depletion on antidepressant-like effects of (R)-ketamine Activation of CSF1R is essential for survival in microglia [66].”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“In contrast, other brain regions such as hippocampus and nucleus accumbens are known to play a role in depression-like phenotypes [27, 41, 48, 50, 77, 78].”
BackgroundM2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination
Miron, V. E., Boyd, A., Zhao, J.-W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., van Wijngaarden, P., Wagers, A. J., Williams, A., Franklin, R. J. M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3469 · Cited by 1,777 · cited 2×
“S9), consistent with the previous report [68].”
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654 · cited 1×
“[45] reported that direct injection of BDNF in the hippocampus caused long-lasting (i.”
BackgroundSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 2×
“Second, we selected mPFC of mouse brain since mPFC is implicated in depression-like phenotypes [27, 47, 48].”
MethodNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609 · cited 1×
“In contrast, (2R,6R)HNK (the metabolite from (R)-ketamine) [28] did not activate Bdnf exon IV promoter whereas its parent compound (R)-ketamine significantly activated Bdnf exon IV promoter (Fig.”
BackgroundA standardized protocol for repeated social defeat stress in mice
Golden, S. A., Covington, H. E., Berton, O., & Russo, S. J. (2011) · Nature Protocols · doi:10.1038/nprot.2011.361 · Cited by 1,581
DNA Methylation-Related Chromatin Remodeling in Activity-Dependent Bdnf Gene Regulation
Martinowich, K., Hattori, D., Wu, H., Fouse, S., He, F., Hu, Y., Fan, G., & Sun, Y. E. (2003) · Science · doi:10.1126/science.1090842 · Cited by 1,405
MeCP2 Is a Transcriptional Repressor with Abundant Binding Sites in Genomic Chromatin
Nan, X., Campoy, F. J., & Bird, A. (1997) · Cell · doi:10.1016/s0092-8674(00)81887-5 · Cited by 1,275 · cited 1×
“MeCP2 is a transcriptional repressor identified as the protein that binds to methylated CpG sites [72].”
BackgroundKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Derepression of BDNF Transcription Involves Calcium-Dependent Phosphorylation of MeCP2
Chen, W. G., Chang, Q., Lin, Y., Meissner, A., West, A. E., Griffith, E. C., Jaenisch, R., & Greenberg, M. E. (2003) · Science · doi:10.1126/science.1086446 · Cited by 1,232
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Enache, D., Pariante, C. M., & Mondelli, V. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.06.015 · Cited by 615 · cited 1×
“A recent meta-analysis using positron emission tomography data showed increased expression of microglia in the brain of patients with depression [71].”
MethodR-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Self-citationKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression
Chang, Q., Khare, G., Dani, V., Nelson, S., & Jaenisch, R. (2006) · Neuron · doi:10.1016/j.neuron.2005.12.027 · Cited by 578 · cited 1×
“It is known that methyl-CpG-binding protein 2 (MeCP2) is a transcriptional regulator of BDNF [53, 62, 63].”
BackgroundBrain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
Castrén, E., & Monteggia, L. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.008 · Cited by 540
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
Targeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
Ketamine: A Paradigm Shift for Depression Research and Treatment
Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.005 · Cited by 455
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060647 · Cited by 431
Phillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418
Vollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00042-9 · Cited by 413
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359 · cited 1×
“Importantly, meta-analyses showed that the effect sizes of (R,S)-ketamine are larger than those of other NMDAR antagonists [15, 16], suggesting that NMDAR does not play a major role in the robust antidepressant effects of (R,S)-ketamine.”
BackgroundR (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Self-citationHashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
Self-citationAn insight into iTRAQ: where do we stand now?
Evans, C., Noirel, J., Ow, S. Y., Salim, M., Pereira-Medrano, A. G., Couto, N., Pandhal, J., Smith, D., Pham, T. K., Karunakaran, E., et al. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-5918-6 · Cited by 300 · cited 1×
“The isobaric Tags for Relative and Absolute Quantification (iTRAQ)-based proteomic technique has been widely used in proteomic workflows relative quantification [46].”
MethodKetamine for rapid reduction of suicidal ideation: a randomized controlled trial
Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715001506 · Cited by 297 · cited 1×
“Furthermore, (R,S)ketamine rapidly reduced suicidal ideation in patients with severe depression [13, 14].”
BackgroundZhang, J.-C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., Li, S.-X., Shirayama, Y., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu077 · Cited by 289
Self-citationPharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271
Ebert, B., Mikkelsen, S., Thorkildsen, C., & Borgbjerg, F. M. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01116-3 · Cited by 270 · cited 4×
“Given the affinity of two enantiomers at NMDAR [25], it is unlikely that NMDAR plays a major role in the activation of Bdnf exon IV promotor by (R)-ketamine.”
BackgroundInfluentialThe future of rodent models in depression research
Gururajan, A., Reif, A., Cryan, J. F., & Slattery, D. A. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0221-6 · Cited by 269 · cited 1×
“The advantages and limitations of animal models such as CSDS for translation in humans were pointed [76].”
BackgroundIntravenous arketamine for treatment-resistant depression: open-label pilot study
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01110-5 · Cited by 257
Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Self-citationYang, C., Ren, Q., Qu, Y., Zhang, J.-C., Ma, M., Dong, C., & Hashimoto, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.016 · Cited by 250 · cited 2×
“We previously reported that ERK plays a role in the antidepressant-like effects of (R)-ketamine in CSDS model [30].”
BackgroundResultSelf-citationMolecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248 · cited 1×
“Further study using these mice with depression-like phenotypes is needed [24].”
BackgroundSelf-citationKetamine: A tale of two enantiomers
Jelen, L. A., Young, A. H., & Stone, J. M. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959644 · Cited by 246
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine
Hashimoto, K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113935 · Cited by 236
Self-citationShirayama, Y., & Chaki, S. (2006) · Current Neuropharmacology · doi:10.2174/157015906778520773 · Cited by 225 · cited 1×
“In contrast, other brain regions such as hippocampus and nucleus accumbens are known to play a role in depression-like phenotypes [27, 41, 48, 50, 77, 78].”
BackgroundSu, T.-P., Chen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Gueorguieva, R., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Krystal, J. H. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.94 · Cited by 209
Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Self-citationZhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., & Hashimoto, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4062-3 · Cited by 183 · cited 1×
“In contrast, other brain regions such as hippocampus and nucleus accumbens are known to play a role in depression-like phenotypes [27, 41, 48, 50, 77, 78].”
BackgroundSelf-citationChang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.-M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.008 · Cited by 176
Self-citationLiu, W., Wang, J., Xie, Z.-M., Xu, N., Zhang, G.-F., Jia, M., Zhou, Z., Hashimoto, K., & Yang, J. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4128-2 · Cited by 169
Self-citationKryst, J., Kawalec, P., Mitoraj, A. M., Pilc, A., Lasoń, W., & Brzostek, T. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00097-z · Cited by 159
A historical review of antidepressant effects of ketamine and its enantiomers
Wei, Y., Chang, L., & Hashimoto, K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172870 · Cited by 157
Self-citationYao, W., Zhang, J.-C., Ishima, T., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., Wu, J., Suganuma, H., et al. (2016) · Scientific Reports · doi:10.1038/srep30659 · Cited by 154
Self-citationA Positive Autoregulatory BDNF Feedback Loop via C/EBPβ Mediates Hippocampal Memory Consolidation
Bambah-Mukku, D., Travaglia, A., Chen, D. Y., Pollonini, G., & Alberini, C. M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0324-14.2014 · Cited by 145 · cited 1×
“Effects of two ketamine enantiomers on BDNF transcription It is reported that CREB functions as a transcription activator of BDNF via motif ahead of Bdnf exon IV [60, 61].”
BackgroundMolecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132
Self-citationHashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0692-7 · Cited by 127
Self-citationYi, L.-T., Li, J., Liu, B.-B., Luo, L., Liu, Q., & Geng, D. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130169 · Cited by 119
Zhang, K., Yang, C., Chang, L., Sakamoto, A., Suzuki, T., Fujita, Y., Qu, Y., Wang, S., Pu, Y., Tan, Y., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0733-x · Cited by 119 · cited 4×
“We found that partial depletion of microglia in the mPFC by PLX3397 blocked antidepressant-like effects of (R)-ketamine in CSDS susceptible mice, consistent with recent report [64].”
BackgroundMethodResultSelf-citationZhang, J., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., Wu, J., Ushida, Y., Suganuma, H., et al. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.10.004 · Cited by 116
Self-citationYao, W., Lin, S., Su, J. Y., Cao, Q., Chen, Y., Chen, J., Zhang, Z., Hashimoto, K., Qi, Q., & Zhang, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01261-6 · Cited by 114 · cited 2×
“It is known that methyl-CpG-binding protein 2 (MeCP2) is a transcriptional regulator of BDNF [53, 62, 63].”
BackgroundResultSelf-citationSustained Effects of Rapidly Acting Antidepressants Require BDNF-Dependent MeCP2 Phosphorylation
Kim, J.-W., Autry, A. E., Na, E. S., Adachi, M., Björkholm, C., Kavalali, E. T., & Monteggia, L. M. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00868-8 · Cited by 113 · cited 2×
“In contrast, a recent study showed that phosphorylation of MeCP2 is essential for the sustained antidepressant-like effects of (R,S)-ketamine in mice [73].”
MethodResultRen, Q., Ma, M., Yang, C., Zhang, J.-C., Yao, W., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.157 · Cited by 100 · cited 1×
“In contrast, other brain regions such as hippocampus and nucleus accumbens are known to play a role in depression-like phenotypes [27, 41, 48, 50, 77, 78].”
BackgroundSelf-citationA Synaptic Locus for TrkB Signaling Underlying Ketamine Rapid Antidepressant Action
Lin, P.-Y., Ma, Z. Z., Mahgoub, M., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109513 · Cited by 99
Yang, C., Han, M., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.03.034 · Cited by 91
Self-citationShirayama, Y., & Hashimoto, K. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0718-1 · Cited by 79 · cited 3×
“In contrast, other brain regions such as hippocampus and nucleus accumbens are known to play a role in depression-like phenotypes [27, 41, 48, 50, 77, 78].”
BackgroundMethodSelf-citationRegional differences in dendritic spine density confer resilience to chronic social defeat stress
Qu, Y., Yang, C., Ren, Q., Ma, M., Dong, C., & Hashimoto, K. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2017.16 · Cited by 68 · cited 1×
“It is suggested that reduced dendritic spine density in the mPFC of CSDS susceptible mice might be involved in depression-like behaviors [74, 75].”
BackgroundSelf-citationZhang, K., Sakamoto, A., Chang, L., Qu, Y., Wang, S., Pu, Y., Tan, Y., Wang, X., Fujita, Y., Ishima, T., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01092-z · Cited by 63 · cited 1×
“The results suggest that (R)-ketamine shows longlasting antidepressant-like effects in CSDS model, consistent with our previous reports [27, 30, 64, 65].”
ResultSelf-citationTian, Z., Dong, C., Fujita, A., Fujita, Y., & Hashimoto, K. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.07.003 · Cited by 62
Self-citationZhang, J., Qu, Y., Chang, L., Pu, Y., & Hashimoto, K. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz048 · Cited by 55 · cited 1×
“It is suggested that reduced dendritic spine density in the mPFC of CSDS susceptible mice might be involved in depression-like behaviors [74, 75].”
BackgroundSelf-citationHashimoto, K. (2016) · Psychological Medicine · doi:10.1017/s0033291716000969 · Cited by 54
Self-citationComputer-Assisted Generation of a Protein-Interaction Database for Nuclear Receptors
Albert, S., Gaudan, S., Knigge, H., Raetsch, A., Delgado, A., Huhse, B., Kirsch, H., Albers, M., Rebholz‐Schuhmann, D., & Koegl, M. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0424 · Cited by 41 · cited 1×
“A computer-assisted generation of a protein-interaction database suggests that NRBP might bind to CREB [57].”
BackgroundHooper, J. D., Baker, E. G., Ogbourne, S. M., Sutherland, G. R., & Antalis, T. (2000) · Genomics · doi:10.1006/geno.2000.6167 · Cited by 35 · cited 1×
“NRBP1 is an adapter protein that is ubiquitously expressed across all cell types, and it plays a role in cellular homeostasis [55, 56].”
Backgroundde Carvalho, C. R., Lopes, M. W., Constantino, L. C., Hoeller, A. A., Melo, H. M., Guarnieri, R., Linhares, M. N., Bortolotto, Z. A., Prediger, R. D., Latini, A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01203-0 · Cited by 33
Yang, Y. H., Ishima, T., Wan, X., Wei, Y., Chang, L., Zhang, J., Qu, Y., & Hashimoto, K. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01325-0 · Cited by 33
Self-citationNuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase
Kerr, J. S., & Wilson, C. H. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130069 · Cited by 32 · cited 1×
“NRBP1 is an adapter protein that is ubiquitously expressed across all cell types, and it plays a role in cellular homeostasis [55, 56].”
BackgroundWang, H., Zhang, Y., Li, H., Zeng, W., & Qiao, M. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5125 · Cited by 31 · cited 1×
“It is also known that phosphorylation of ERK could activate the transcription factor CREB, resulting in the regulation of BDNF transcription [58, 59].”
Zhu, J., Hawkins, E., Phillips, K., & Deshpande, L. S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134710 · Cited by 27
Cited by
Brain–gut–microbiota axis in depression: A historical overview and future directions
Chang, L., Wei, Y., & Hashimoto, K. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.004 · Cited by 377
Self-citationKetamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“Other proposed mechanisms for ketamine ’ s antidepressant action include ketamine enantiomers [10] and metabolites [11], the potential role of in fl ammatory processes [12], and non-neuronal contributions including those from microglia [13], among others.”
BackgroundThe molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
The antidepressant actions of ketamine and its enantiomers
Johnston, J. N., Henter, I. D., & Zarate, C. A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108431 · Cited by 108
Roles of microglia in adult hippocampal neurogenesis in depression and their therapeutics
Fang, S., Wu, Z., Guo, Y., Zhu, W., Wan, C., Yuan, N., Chen, J., Hao, W., Mo, X., Guo, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1193053 · Cited by 96
“Recently, our group found that (R)- ketamine exerts an antidepressant effect by inhibiting microglial ERK-NRBP1-CREB-BDNF signaling in the mPFC of CSDS mice, suggesting that the regulation of ketamine involves microglia and BDNF (230).”
BackgroundSelf-citation
Metadata
- Authors
- Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C.
- Affiliations
- Jinan University (CN)
- Central South University (CN)
- Chiba University (JP)
- Corresponding author
- Qi, Qi
- Hashimoto, Kenji
- Zhang, Ji-chun
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2021-11-24
- Volume
- 27
- Issue
- 3
- Pages
- 1618-1629
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC9095473
- OpenAlex
- W3216353063
- Cited by
- 216
- References
- 80
- Citations by year
- 2026: 29 · 2025: 44 · 2024: 56 · 2023: 50 · 2022: 36 · 2021: 1
- FWCI
- 18.94
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-12-08)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- MEXT | Japan Society for the Promotion of Science (21H02846, 24116006)
- National Natural Science Foundation of China (81973341)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- (R)-ketamine, antidepressant effects, microglia, ERK signaling, NRBP1, CREB, brain-derived neurotrophic factor, chronic social defeat stress, depression, medial prefrontal cortex, MeCP2, microglial depletion, dendritic spine density, enantiomers, rapid-acting antidepressants
- MeSH terms
- Animals, Antidepressive Agents, Depression, Humans, Ketamine, Mice, Inbred C57BL, Stress, Psychological, Microglia, Receptors, Cytoplasmic and Nuclear, Brain-Derived Neurotrophic Factor, Vesicular Transport Proteins, Extracellular Signal-Regulated MAP Kinases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.